Publications dans lesquelles il/elle collabore avec María Jesús Garrido Cid (20)

2024

  1. Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice

    Acta Pharmacologica Sinica

  2. Lipid-based nanosystems: the next generation of cancer immune therapy

    Journal of Hematology and Oncology, Vol. 17, Núm. 1

2023

  1. Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling

    Clinical Pharmacology and Therapeutics, Vol. 114, Núm. 3, pp. 623-632

2022

  1. Stealth nanoparticles in oncology: Facing the PEG dilemma

    Journal of Controlled Release, Vol. 351, pp. 22-36

2021

  1. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  2. Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration

    Frontiers in Pharmacology, Vol. 12

  3. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1

    British Journal of Cancer, Vol. 124, Núm. 7, pp. 1275-1285

  4. Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors

    Cancers, Vol. 13, Núm. 20

2020

  1. Quantification of pharmacokinetic profiles of pd-1/pd-l1 antibodies by validated elisas

    Pharmaceutics, Vol. 12, Núm. 6, pp. 1-16

2019

  1. A new immune-nanoplatform for promoting adaptive antitumor immune response

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 13-25

2018

  1. Immunoliposomes in clinical oncology: State of the art and future perspectives

    Journal of Controlled Release, Vol. 275, pp. 162-176

2016

  1. EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model

    Nanomedicine, Vol. 11, Núm. 5, pp. 465-477

2015

  1. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer

    Journal of Controlled Release, Vol. 210, pp. 26-38

2013

  1. Efficient serum-resistant lipopolyplexes targeted to the folate receptor

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 83, Núm. 3, pp. 358-363

  2. Liposomes, a promising strategy for clinical application of platinum derivatives

    Expert Opinion on Drug Delivery, Vol. 10, Núm. 6, pp. 829-844

2012

  1. Application of different methods to formulate PEG-liposomes of oxaliplatin: Evaluation in vitro and in vivo

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 81, Núm. 2, pp. 273-280

2011

  1. Efficient gene delivery by EGF-lipoplexes in vitro and in vivo

    Nanomedicine, Vol. 6, Núm. 1, pp. 89-98

2010

  1. Application of non-aggressive sample preparation and electrothermal atomic absorption spectrometry to quantify platinum in biological matrices after cisplatin nanoparticle administration

    Microchemical Journal, Vol. 96, Núm. 2, pp. 415-421

  2. Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 74, Núm. 2, pp. 265-274

2009

  1. Biopharmaceutic and pharmacodynamic modeling of the in vitro antiproliferative effect of new controlled delivery systems of cisplatin

    European Journal of Pharmaceutical Sciences, Vol. 37, Núm. 3-4, pp. 341-350